Close Menu

Santaris Pharma and Miragen Therapeutics announced this week that they have formed a strategic alliance to develop microRNA-targeting drugs for cardiovascular disease.

Under the deal, Miragen will use Santaris' proprietary locked nucleic acid technology to develop single-stranded RNAs against its own miRNA targets related to cardiovascular disease. In exchange, Santaris received an undisclosed minority interest in Miragen, and is eligible to receive milestones and royalties related to the achievement of certain development and regulatory goals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The University of California, Berkeley's Jennifer Doudna reflects at Science on the anniversary of the announcement of the birth of twin girls who underwent genome editing.

By studying its enamel proteome, researchers have found the ancient ape Gigantopithecus blacki belongs to a sister clade to that of orangutans.

Bloomberg Businessweek discusses genomics with BGI's Wang Jian.

In Science this week: researchers find transplanting the gut microbiome in mice affects physiology, and more.